Showing results (1-10 of 400) with videos related to
Sort By:
Pageof 40
Multiple Sclerosis International|March 4, 2014
Gray matters in multiple sclerosis: cognitive impairment and structural MRISilvia Messina, Francesco PattiExpert Opinion on Drug Metabolism & Toxicology|June 26, 2013
The pharmacokinetics of glatiramer acetate for multiple sclerosis treatmentSilvia Messina, Francesco PattiExpert Opinion on Drug Safety|April 1, 2015
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosisEmanuele D'Amico, Silvia Messina, Cinzia Caserta, et al.European Neurology|February 23, 2016
Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 YearsFrancesco PattiPatient Preference and Adherence|February 19, 2010
Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherenceFrancesco PattiNeurodegenerative Disease Management|January 19, 2019
Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studiesFrancesco PattiExpert Opinion on Investigational Drugs|August 11, 2012
Treatment of cognitive impairment in patients with multiple sclerosisFrancesco PattiJournal of Neurology|February 10, 2015
Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania, SicilyFrancesco Patti, Alessandra Nicoletti, Silvia Messina, et al.Therapeutic Advances in Neurological Disorders|December 25, 2010
Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS StudyFrancesco Patti, Maria Pia Amato, Stefano Bastianello, et al.Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumabFrancesco Patti, Angelo PappalardoPageof 40